Catamaran Bio General Information Description.

Catamaran bio. Based biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer launched with 42m in Series A financing. Strategic and results-oriented executive with more than 25 years of experience in the biotechnology industry--spanning legal affairs pharma partnering and operations. Our lead CAR-NK cell therapy for hematologic.

At Catamaran our mission is to harness the power of our proprietary TAILWIND Platform to develop safe and effective off-the-shelf allogeneic immune cell therapies for the treatment. Catamaran Bio Inc a Cambridge Mass. Founded by pioneers in NK cell engineering and biology and steered by a leadership team with deep cell therapy experience Catamaran has assembled the collective expertise.

Using our TAILWIND Platform we are engineering our lead CAR-NK cell therapy for solid tumors with an optimized CAR architecture for appropriate cell activation a potency-boosting biological switch for efficacy in the hostile tumor microenvironment and a cytokine to provide functional persistence. The company engages in using genetic engineering of natural killer cells to target a number of therapeutic areas with high unmet needs enabling medical practitioners and individuals to procure therapies for treating their conditions. Catamaran Bio is developing novel off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers including solid tumors.

Catamaran Bios Chief Scientific Officer is Vipin Suri. Catamaran Bio sets sail with 42M to create off-the-shelf CAR-NK treatments. Our diverse backgrounds and experiences will keep us resilient when facing headwinds as we pioneer groundbreaking science.

See the full leadership team at Craft. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative. Patients drive our passion and creativity.

At Catamaran our mission is to harness the power of our proprietary TAILWIND Platform to develop safe and effective off-the-shelf allogeneic immune cell therapies for the treatment of patients with cancer and immune disorders-----Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies. Mark Boshar Chief Operating Officer and 4 others. We are committed to equal employment opportunity regardless of race color.